Increased Expression of Cell-Cell Signaling Genes by Stimulated Mononuclear Leukocytes in Patients with Previous Atherothrombotic Stroke A Whole Genome Expression Profile Study by Grond-Ginsbach, Caspar et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Paper 
 Eur Neurol 2009;62:30–39 
 DOI: 10.1159/000215878 
 Increased Expression of Cell–Cell Signaling 
Genes by Stimulated Mononuclear Leukocytes in 
Patients with Previous Atherothrombotic Stroke 
 A Whole Genome Expression Profile Study 
 Caspar Grond-Ginsbach a    Solveig Horstmann a    Manuela Hummel b    Tina Wiest a    
Cornelius Honold a    Karin Pfleger a    Manfred Hergenhahn †, c    Monika Hollstein c    
Annette Weninger c    Yuri Knyazev c    Ulrich Mansmann b    Simone Wagner a    
Armin J. Grau d  
 a  Department of Neurology, University of Heidelberg,  Heidelberg ,  b  IBE, Medical School, LMU Munich,  Munich, 
 c  Department of Genetic Alterations in Carcinogenesis, German Cancer Research Center,  Heidelberg , and 
 d  Department of Neurology, Klinikum der Stadt Ludwigshafen,  Ludwigshafen am Rhein , Germany 
of PBMCs, a condition mimicking bacterial infection, induces 
differential expression of a group of cell–cell signaling genes 
in patients with previous atherothrombotic stroke. This find-
ing can be caused by genetic differences between both 
groups, but acquired risk factors, medication and technical 
factors may also have contributed to the result. 
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 Introduction 
 Several lines of evidence indicate that inflammation 
plays an important role in stroke and other vascular dis-
eases. Atherosclerosis is now viewed as an inflammatory 
disease  [1, 2] and markers of inflammation including leu-
kocyte counts are predictors of first and recurrent isch-
emic events  [3] . Multiple case-control studies and a large 
study based on the case series method showed that recent 
acute infections are triggering factors for stroke; further-
more, chronic infections are discussed as stroke risk fac-
tors  [4, 5] . There is not one single microbial pathogen or 
a definable group of microbes that is associated with 
stroke risk and, most likely, the inflammatory response 
upon infections leading to a procoagulant state repre-
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 Abstract 
 Background/Aims: Inflammation plays an important role in 
atherosclerosis and stroke. Acute infections are recognized 
as trigger factors for ischemic stroke.  Methods: In this whole 
genome expression profile study of 15 patients and 15 con-
trol subjects, we tested the hypothesis that patients with a 
history of atherothrombotic stroke show enhanced tran-
scription of inflammatory genes in circulating leukocytes. 
RNA from unstimulated or lipopolysaccharide (LPS)-stimu-
lated peripheral blood mononuclear cells (PBMCs) was ana-
lyzed with Affymetrix U133A GeneChips using a pooling de-
sign. Expression of single genes and functional groups of 
genes was analyzed by global statistical tests.  Results: A to-
tal of 10,197 probe sets showed positive calls. After correc-
tion for multiple testing no single probe set revealed signif-
icant differences either without or with LPS stimulation. 
However, significant global expression differences were 
found upon LPS stimulation for the group of genes that are 
involved in cell–cell signaling.  Conclusion: LPS stimulation 
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sents the major pathogenetic mechanism linking infec-
tion and stroke  [6] . The individual inflammatory re-
sponse on external stimuli is under strong genetic control 
and it is an intriguing hypothesis that the strength of this 
inflammatory response is associated with stroke risk. In 
fact, a case-control study showed that the odds of stroke 
increase along the number of proinflammatory polymor-
phisms in several inflammatory genes  [7] . Furthermore, 
intima-media thickness as a surrogate parameter of 
stroke risk is associated with the number of proinflam-
matory genotypes  [8] .
 Based on this background we hypothesized that pa-
tients with a history of stroke due to atherosclerotic large 
artery disease show enhanced expression of inflamma-
tory genes in circulating mononuclear leukocytes upon 
in vitro stimulation with lipopolysaccharide (LPS), a con-
dition mimicking acute bacterial infections, or possibly 
already in the unstimulated state. In order to test this hy-
pothesis, we used microarray (GeneChips) technology 
that allows simultaneous analysis of thousands of tran-
scripts from a tissue sample. Recently, transcriptome 
analyses of circulating leukocytes have been performed 
in patients with acute stroke  [9–11] . Genes involved in 
inflammatory response, coagulation and tissue remodel-
ing were found to be significantly upregulated during 
acute stroke, but study results are at variance. In contrast 
to these studies, here we investigated patients at least 3 
months after atherothrombotic stroke to study whether 
gene transcription in circulating leukocytes shows in-
creased stimulability or is even chronically upregulated 
in these patients (unstimulated state).
 Patients and Methods 
 Stroke Survivors and Healthy Referents 
 Patients recovering from ischemic stroke due to severe intra-
cranial or extracranial ( 1 70%) atherosclerotic stenosis at least 3 
months before inclusion were recruited for this study. Ischemic 
stroke was defined as an acute ischemic lesion on neuroimaging 
or an acute neurological deficit of vascular origin lasting  1 24 h. 
We enrolled unrelated patients and healthy subjects  1 18 years 
who were born of German parents. The stringent inclusion and 
exclusion criteria aimed at the selection of a study sample of pa-
tients with highest possible homogeneity and without serious co-
morbidities or serious post-stroke handicaps that might possibly 
interfere with the gene expression of the peripheral white blood 
cells. Excluded from the study were subjects with a history of renal 
or liver diseases, alcohol abuse, psychiatric disorders, acute or 
chronic inflammatory diseases, tumor, trauma, surgical treat-
ment, myocardial infarct or other vascular diseases within the 
last 3 months. None of the analyzed patients was submitted to 
angioplasty with stenting.
 Husbands or wives of the patients were asked to participate in 
the study as healthy controls, in order to match both study groups 
as to lifestyle, social environment and diet. However, due to the 
fact that most patients were men, this selection of control subjects 
resulted in different ages and gender percentages among the study 
groups. Histories of vascular diseases or vascular risk factors were 
additional exclusion criteria for the control group ( table 1 ). All 
patients were independent and had recovered well from stroke 
(modified Rankin scale 0 or 1). Blood sampling of all patients and 
control persons was performed between 10 and 12 a.m. All sam-
ples were handled by the same technician in the same laboratory. 
The study protocol was approved by the local ethics committee 
and all participants gave written informed consent.
 Preparation of Peripheral Blood Mononuclear Cells and 
Isolation of RNA 
 Peripheral blood mononuclear cell (PBMC) transcriptomes 
were studied from 15 stroke survivors (survivors) and 15 healthy 
control subjects (referents). RNA was prepared from PBMCs ei-
ther immediately after blood sampling (resting cells) or after 2-
hour incubation of isolated PBMCs with LPS. 20 ml free-flowing 
peripheral venous blood was taken into pyrogen-free syringes 
containing EDTA and cooled on ice. PBMCs were isolated imme-
diately by 12-min density-gradient centrifugation at 4 ° C using 
pre-cooled Ficoll-Paque (Amersham Biosciences, Uppsala, Swe-
Table 1. Baseline characteristics, vascular risk factors and medi-
cation of survivors and referents
Cases 
(n = 15)
Referents 
(n = 15)
Women 3 11
Mean age, years (range) 70.2 (56–83) 65.4 (56–74)
Mean time after stroke
months (range) 14 (5–32) –
Modified Rankin scale <2 15 –
NIHSS at acute stroke ≤3 11 –
Carotid angioplasty or stenting1 6 –
Cigarette smoking 4 0
Arterial hypertension 12 0
Diabetes mellitus 4 0
Hypercholesterolemia 7 0
Peripheral occlusive arterial disease 2 0
Coronary artery disease 2 0
ASA 9 0
Clopidogrel 6 0
ACE inhibitor 7 0
Statin 9 0
Diuretics 5 0
ASA = Acetylsalicylic acid; ACE = angiotensin-converting en-
zyme.
1 Carotid angioplasty or stenting in the first month following 
acute stroke.
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den). An aliquot of each isolate was analyzed in a cell counter 
( table 2 ). After being washed in PBS at 4 ° C half of the leukocyte 
suspension was diluted in 10 ml RPMI-1640 to which LPS from 
 Salmonella abortus equi (500 pg/ml final concentration, Bier-
mann, Bad Nauheim, Germany) had been added. After incuba-
tion at 37 ° C for 120 min the cells were spun down, washed in ice-
cold PBS and passed to 1.0 ml Trizol reagent. The second half of 
the leukocytes was processed without delay for RNA isolation af-
ter density gradient centrifugation. For cells that were not treated 
with LPS the whole procedure from blood sampling onto the lysis 
of the leukocytes in Trizol reagent was performed within 37 min 
and under continuous cooling at 4 ° C. For the isolation of the 
RNA by Trizol we followed the instructions of the provider. After 
isopropanol precipitation and 2 washes in 70% ethanol the RNA 
pellet was dissolved in RNase-free water and subsequently puri-
fied on an RNeasy MinElute Cleanup column (Qiagen, Valencia, 
Calif., USA). The 14-  l eluate from the Cleanup column was ana-
lyzed by standard photometry (for RNA quantification) and with 
an Agilent 2100 Caliper LabChip Bioanalyzer (Agilent Technolo-
gies, Palo Alto, Calif., USA) to test for the integrity of the RNA.
 Affymetrix GeneChip U133A Microarray Studies 
 RNA from the PBMCs of 5 subjects of each group was pooled 
at equal amounts for GeneChip analysis and analyzed on a single 
U133A GeneChip. Twelve array hybridization reactions were per-
formed (three pools of LPS-stimulated cells and three pools of 
resting cells from stroke survivors, and three corresponding pools 
of material from referents with and without LPS), resulting in 12 
readings for each probe set.
 During the whole procedure of cRNA labeling and array hy-
bridization, we followed the protocols from Affymetrix Inc. (San-
ta Clara, Calif., USA). Two micrograms of RNA from each of 5 
different samples were pooled for the synthesis of cDNA. This 10-
  g mRNA sample of total cellular RNA was converted to double-
stranded cDNA using Superscript (Gibco-Invitrogen, Karlsruhe, 
Germany) with a T7-(dT)24 primer containing the T7 RNA poly-
merase promoter. The cDNA was in vitro transcribed to biotinyl-
ated complementary RNA (cRNA) by incorporating biotin-CTP 
and biotin-UTP using the Enzo BioArray High Yield RNA label-
ing kit (Enzo Diagnostics, Farmingdale, N.Y., USA). Biotinylated 
cRNA from each sample was fragmented and 15   g of the frag-
mented cRNA were used for the preparation of 300   l hybridiza-
tion mix (80   l were probed on a Test 3 Array and 200   l on a 
U133A Array). Arrays were hybridized for 16 h at 45 ° C with con-
stant rotation at 60 rpm. Following washes, arrays were sequen-
tially stained with streptavidin R-phycoerythrin (Molecular 
Probes, Eugene, Oreg., USA), biotinylated goat anti-streptavidin 
(Vector Laboratories, Burlingame, Calif., USA) and another strep-
tavidin-phycoerythrin for signal amplification. After a series of 
washes the GeneChips were scanned with an argon-ion laser mi-
croscope (Hewlett-Packard, Palo Alto, Calif., USA) for fluores-
cence signal detection. All washes and staining procedures were 
performed on an Affymetrix Fluidics station. The raw expression 
data derived from Affymetrix Micro-array Suite 4.0.1 software 
gave each transcript an absolute expression level (signal intensity) 
and a ‘present’ or ‘absent’ call based on the signal/noise ratio.
 Real-Time Reverse-Transcribed Polymerase Chain Reaction 
Analysis 
 As an independent validation of the Affymetrix results, the 
transcripts from 3 different genes were quantified by reverse-
transcribed polymerase chain reaction (RT-PCR). In these exper-
iments we did not use pooled RNA samples, but analyzed 10 in-
dividual RNA specimens from patients and 10 samples from ref-
erent subjects. Five of the RNA samples were from stroke survivors 
and healthy subjects that were previously studied by Affymetrix 
Arrays, five further RNA samples were taken from additional 
control subjects and additional stroke survivors with baseline 
characteristics similar to the other patients and referents.
 Real-time RT-PCRs of ATF3, NF  B2 and IL1F9 were carried 
out in 96-well PCR plates with a SYBR-Green PCR kit (Applied 
Biosystems, Weiterstadt, Germany) in an ABI PRISM 5700 Se-
quence Detector (Applied Biosystems) following standard proce-
dures. As housekeeping gene we used glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). The following primers were used: 
GGTCTCTGCCTCGGAAGTGA and TGCTTGTTCTGGAT C-
CGAAA for ATF3; CAGTGAGAAGGGCCGAAAGA and AGC-
ACGAGGTGGGTCACTGT for NFKB2; GCACTCCAGGAGA-
CGCTGAT and ACTTCGTGGAACTGCCACAAG for Il1F9, 
and TGGGTGTGAACCATGAGAAG and GCTAAGC AGTTG-
GTGGTGC for GAPDH. The amplification reactions were per-
formed in duplicate. For relative quantification of the transcripts, 
a standard curve was calculated by measuring serially diluted 
amounts of cDNA.
Table 2. Composition of PBMC isolate after density gradient centrifugation
Cases Referents p
P1 P2 P3 P1 P2 P3
Lymphocytes, % 77 84 80 76 82 81 n.s.
Monocytes, % 17 14 13 17 16 12 n.s.
Granulocytes, % 6 2 7 7 2 8 n.s.
Platelets, !1,000/ml 119 119 149 126 122 147 n.s.
The proportion of lymphocytes, monocytes and granulocytes within the total amount of leukocytes was 
measured for each PBMC isolate. Mean values were calculated for each pool of 5 individuals. The number of 
platelets was standardized for a PBMC isolate volume containing 107 leukocytes.
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 Evaluation of GeneChip Data 
 The statistical analysis was carried out with the open source 
software R (http://www.r-project.org/, version 2.3.0) and Bio-
conductor (http://www.bioconductor.org/, version 1.8)  [12] . The 
U133A raw data were analyzed after GC-RMA (robust multi-ar-
ray) normalization  [13] . Hybridization intensities were compared 
between pooled samples of survivors and referents for each probe 
set. Log2 ratios (= log-fold changes, logFC) were calculated. Gene 
expression of resting PBMCs (called ‘base level’ gene expression) 
was compared between survivors and referents. We also compared 
survivors and referents as to the difference in gene expression be-
tween LPS-treated and resting cells (LPS responsiveness). Correc-
tion for multiple testing was carried out by controlling the false 
discovery rate according to Benjamini and Hochberg  [14] or by the 
Bonferroni method. Moreover, predefined groups of genes were 
analyzed with a global ANCOVA test for each group or with non-
parametric Kolmogorov-Smirnov rank statistics  [15, 16] . The glob-
al ANCOVA approach is a test for the association between expres-
sion values and clinical entities within a well-defined group of 
genes. If the mean expression level for at least one of these genes 
differs between phenotypes, the global null hypothesis is violated. 
Significance is assessed by a permutation approach (permutation 
of phenotype labels). This global test is freely available as Biocon-
ductor package (Global ANCOVA) . The Kolmogorov-Smirnov ap-
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 Fig. 1. Flowchart showing the design of the 
study. PBMCs from patients with previous 
atherothrombotic stroke (stroke survi-
vors) and from controls (healthy referents) 
were analyzed under two conditions (base 
level gene expression and stimulated gene 
expression after in vitro LPS treatment). 
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proach assesses whether the global level of differential expression 
within a group of genes is outstanding compared to the global lev-
el of differential expression in the remaining genes. In the proce-
dure all genes on the array are ranked due to a score for differential 
expression. While exploring the ranks of genes, the method an-
swers the question whether the difference in expression for a given 
set of genes is more pronounced compared with the differential 
expression in the remaining genes. A p value for each gene group 
is computed by a permutation approach (permutation of genes).
 Definition of Gene Groups 
 Predefined functional gene groups were selected chosen from 
the Gene Ontology (http://www.geneontology.org/) and Kyoto 
Encyclopedia of Genes and Genomes (KEGG; http://www.ge-
nome.jp/kegg/kegg2.html) databases  [17] . Gene Ontology groups 
0006954 (inflammatory response), 0006917 (induction of apopto-
sis), 0006950 (response to stress), 0007596 (blood coagulation), 
0007155 (cell adhesion), 0007267 (cell–cell signaling), 0006955 
(immune response), 0006629 (lipid metabolism) and KEGG 
groups hsa00590 (prostaglandin and leukotriene metabolism), 
hsa04350 (TGF-  -signaling pathway) and hsa0462 (TLR-signal-
ing pathway) were selected. We furthermore analyzed some 
groups of genes identified in GeneScan studies of circulating cells 
from acute stroke patients  [10, 11] as well as a group of genes that 
was reported to be activated by LPS in macrophages  [18] .
 Results 
 PBMCs from 15 stroke survivors and 15 healthy con-
trol subjects (referents) were studied without LPS stimu-
lation as well as upon LPS stimulation (fig. 1). After nor-
malization of the data with GC-RMA, we filtered probe 
sets with present calls in all 12 analyzed RNA pools or at 
least in all 6 LPS-induced pools. Thus, 10,197 probe sets 
(of all 22,263 probe sets of the U133A array) were selected 
and analyzed further. For each probe set logFCs were cal-
culated for base level gene expression as well as for LPS 
responsiveness. LPS stimulation induced dramatic dif-
ferences in the gene expression profiles of PBMCs (online 
Table 3. Tests of groups of genes for differences between survivors and referents
Survivors vs. controls n Base level expression LPS responsiveness
ANCOVA K-S ANCOVA K-S
Gene group p value p value p value p value
GO:6954 inflammation 119 0.65 0.93 0.20 0.24
GO:6917 apoptosis 98 0.85 0.97 <0.001 0.06
GO:6940 stress response 82 0.85 0.95 0.65 0.97
GO:7596 coagulation 40 0.95 0.64 0.10 0.52
GO:7155 cell adhesion 162 1.00 0.76 0.35 0.19
GO:7267 cell–cell signaling 117 0.75 0.22 <0.001 0.04
GO:6955 immune response 298 0.65 0.85 0.25 0.29
GO:6629 lipid metabolism 140 0.55 0.29 0.35 0.92
hsa00590 prostaglandin 24 0.85 0.60 0.25 0.50
hsa04350 TGF- receptor 16 0.15 0.39 0.25 0.38
hsa04620 TLR signaling pathway 96 0.30 0.20 0.15 0.24
LPS-activated genes [18]
Early LPS response 77 0.45 0.91 0.20 0.0001
Late LPS response 67 0.60 0.52 0.20 0.04
Acute stroke [10]
Bonferroni list 198 0.60 1.00 0.40 0.92
Westfall and Young list 85 0.80 0.99 0.55 0.49
Acute stroke [11]
3 h 38 0.35 0.23 0.70 0.95
5 h 431 0.45 0.97 0.40 0.54
24 h 345 0.45 0.58 0.55 0.43
Functional GO (gene ontology) and hsa-KEGG (Kyoto Encyclopedia of Genes and Genomes) groups as well 
as gene groups found in expression profiling studies of acute stroke patients were studied. n refers to the num-
ber of probe sets among the 10,197 present cells analyzed here that identify genes belonging to the group. For 
each gene group the H0 (no difference between survivors and referents) was tested with ANCOVA and Kol-
mogorov-Smirnov-like rank tests. Bold p values indicate p values of <0.05.
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suppl. fig. 1a–d, for all supplementary material, see www.
karger.com/doi/10.1159/000215878). However, the varia-
tion among the microarray data between patients and ref-
erents remained low. 9,715 probe sets (95.3%) had LogFCs 
between –0.4 and +0.4 for base level gene expression, 
which corresponds to nominal fold changes between 0.76 
and 1.32. Only 23 probe sets had logFC  1 1 (online suppl. 
fig. 2a–d ). Variation of LPS responsiveness was slightly 
larger (85.4% of the probe sets had logFC s between –0.4 
and 0.4). We found 124 probe sets with logFC  1 1 after LPS 
stimulation. In none of the 10,197 probe sets analyzed did 
the difference between patients and the reference group 
remain significant after correction for multiple testing 
(Bonferroni or Benjamini and Hochberg), either in base 
level expressions or in LPS responsiveness. The use of less 
conservative methods for correction (like procedures 
that control the false discovery rate) did not result in the 
detection of significant differences either.
 However, when the expression of predefined function-
al groups of genes were analyzed, significant differences 
between patients and controls could be observed after 
LPS stimulation.
 For the analysis of gene groups we chose predefined 
gene ontology groups with possible involvement in stroke 
and some published gene groups with possible relevance 
to stroke or genes responding to LPS ( table 3 ). Two statis-
tical approaches were used to evaluate the differences in 
expression. An analysis of variance-like approach (global 
ANCOVA test) examines differential gene expression 
within a group of genes. A global difference may be found 
if expression values for some of the genes in the group are 
strongly different, or alternatively if many genes show 
slight differences in expression. The Kolmogorov-Smir-
nov rank test asks whether the differential expression for 
a group of genes is more pronounced compared to all the 
remaining genes. If many probe sets in the group of inter-
est have extreme t values, the test considers this group as 
important. As shown in  table 3 , differences between gene 
groups were not significant for base level gene expression. 
However, in the cell–cell signaling gene group, stroke 
survivors showed a stronger gene expression difference 
upon LPS than the referents (significant results according 
to both tests procedures). The significant result of the 
Kolmogorov-Smirnov test suggests that many genes in-
volved in cell–cell signaling are strongly differentially ex-
pressed. Such strong differential expression in most cases 
also provokes a significant result for the global ANCOVA 
test. Regarding genes involved in the LPS response, small 
p values are observed with the Kolmogorov-Smirnov 
procedure but not with global ANCOVA. This may be 
Table 4. Probe sets with highest contribution to the significant test results (top ten in both cases)
Cell–cell signaling (global ANCOVA test)
211122_s_at CXCL11 Hs.518814 Chemokine (C-X-C motif) ligand 11
207442_at G-CSF Hs.2233 Colony-stimulating factor 3 (granulocyte)
210163_at CXCL11 Hs.518814 Chemokine (C-X-C motif) ligand 11
220322_at IL1F9 Hs.211238 Interleukin-1 family member 9
206295_at IL18 Hs.83077 Interleukin-18 (interferon--inducing factor)
206620_at GRAP Hs.546336 GRB2-related adaptor protein
204533_at CXCL10 Hs.413924 Chemokine (C-X-C motif) ligand 10
207691_x_at CD39 Hs.550467 Ectonucleoside triphosphate diphosphohydrolase 1
205767_at EREG Hs.115263 Epiregulin
207426_s_at TNFSF4 Hs.181097 Tumor necrosis factor (ligand) superfamily member 4
Cell–cell signaling (Kolmogorov-Smirnov-like test)
205560_at PCSK5 Hs.368542 Proprotein convertase subtilisin/kexin type 5
211122_s_at CXCL11 Hs.518814 Chemokine (C-X-C motif) ligand 11
207442_at G-CSF Hs.2233 Colony-stimulating factor 3 (granulocyte)
220558_x_at TSPAN32 Hs.271954 Tetraspanin 32
206582_s_at GPR56 Hs.513633 G-protein-coupled receptor 56
210354_at IFNG Hs.856 Interferon-
217496_s_at IDE Hs.500546 Insulin-degrading enzyme
32137_at JAG2 Hs.433445 Jagged 2
206295_at IL18 Hs.83077 Interleukin-18 (interferon--inducing factor)
211506_s_at IL8 Hs.624 Interleukin-8
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due to correlations between genes which are not captured 
with the former approach in contrast to the latter one. 
The significant global ANCOVA result for genes involved 
in apoptosis (and also the relatively small Kolmogorov-
Smirnov p value) suggests that in this group there are 
many moderately differentially expressed genes.
 We further analyzed the group of genes involved
in cell–cell signaling in order to identify which genes 
contributed most strongly to the differences found be-
tween survivors and referents ( table 4 ). This group 
(GO:0007267) is represented by 421 probe sets on the 
U133A array. 117 of these 421 probe sets (identifying 83 
different genes) show present calls in our material. Probe 
sets identifying transcripts of CXCL11, IL18 and granu-
locyte colony-stimulating factor (G-CSF) contributed in 
both statistical test procedures most strongly to the sig-
nificant difference. The upregulation of these genes upon 
LPS was more dramatic in stroke survivors than in refer-
ents ( fig. 2 ).
 We studied the expression of three genes (ATF3, 
NF  B2 and IL1F9) also by real-time RT-PCR in LPS-
treated PBMCs from 5 of the survivors and referents. 
These analyses were moreover repeated in newly isolated 
PBMCs from 5 additional stroke survivors and 5 addi-
tional referents. We chose these three genes as examples 
of genes that are strongly affected by LPS treatment 
(ATF3; see online suppl. fig. 1c ), that are moderately up-
regulated by LPS (NFKB2), and that belong to the cell–
cell signaling proteins encoding genes (IL1F9). The ex-
pression values measured by the Affymetrix GeneScan 
experiments were confirmed by real-time RT-PCR analy-
sis. Significant gene expression differences upon LPS 
were assessed by both methods, but also small and non-
significant expression differences between survivors and 
referents (online suppl. fig. 3).
 Discussion 
 We analyzed circulating PBMCs from patients in the 
chronic stage after stroke and healthy control subjects to 
test the hypothesis that gene expression profiles with and 
without LPS stimulation are persistently different be-
tween both groups. No significant differences in gene ex-
pression were found between resting PBMCs from stroke 
survivors and control samples. Acute infection is a stroke 
risk factor  [5] . Therefore, we stimulated cells with LPS to 
test whether such stimulation increases or evokes gene 
expression differences between both groups possibly in-
dicating that differential responsiveness may be associ-
ated with the proneness to stroke. The group of genes 
involved in cell–cell signaling showed global expression 
differences between groups after LPS stimulation.
 The peripheral inflammatory response during the 
acute phase of stroke was analyzed in earlier studies with 
Affymetrix U133 arrays  [9–11] . Here we studied for the 
first time the gene expression patterns of blood samples 
from patients who have recovered from stroke. We can-
not rule out that some effects of the brain ischemia re-
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 Fig. 2. Base level gene expression ( ) ) and gene expression upon 
LPS ( $ ) for single probe sets.  a COX2.  b CXCL11.  c G-CSF.  d IL18. 
Three pools of RNA were analyzed in each experiment. Y-axis 
shows log2-transformed normalized expression values. 
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main traceable in the PBMC transcriptome even after at 
least 3 months. However, we suspect that our findings 
rather reflect the chronic condition of our patients.
 The high similarity of the expression profiles of the 
survivors and the referents made the discrimination be-
tween statistical noise and real differences between 
groups difficult. To face this difficulty we not only fo-
cused on the study of single genes, but studied genetic 
programs as well. Our data suggest that the LPS respon-
siveness of a group of genes involved in cell–cell signal-
ing differs significantly between patients and referents. 
This difference can be regarded as important since dif-
ferential expression was detected using two statistical 
methods (the global ANCOVA approach and the Kol-
mogorov-Smirnov test). However, both methods have 
their limitations. A limitation of global ANCOVA in 
this case is the small sample size which restrains the 
number of possible permutations of the phenotype la-
bels. The Kolmogorov-Smirnov test has the drawback of 
assuming the independence of variables, a condition 
that is not fulfilled in expression profiling studies since 
gene expression varies for many genes in a coordinated 
way.
 We tried to reduce the heterogeneity within the groups 
by selecting referents without vascular risk factors and 
patients with a good outcome after a mild ischemic stroke 
at least 3 months before inclusion. Moreover, we enrolled 
stroke patients from a single etiologic subgroup – large 
artery atherosclerosis. To avoid methodological variation 
we followed a very strict protocol. Blood sampling of pa-
tients and referents was performed in exactly the same 
way between 10 a.m. and noon. All samples were handled 
by the same technician in the same laboratory. Mono-
nuclear cells were isolated immediately after blood sam-
pling by density gradient centrifugation at 4 ° C. The study 
of PMBCs after LPS stimulation and the comparison of 
resting and stimulated cells from the same subjects are a 
further strength of this study. Limitations of our study 
were the restricted number of subjects and the require-
ment of pooling, which reduced the power of statistical 
tests. Therefore, some minor gene expression differences 
may have been missed in our study. Nevertheless, pooling 
does not affect the estimates of absolute expression values 
or calculated folds (expression ratios of patients and con-
trols). Our observation that not a single gene is strongly 
up- or downregulated is not compromised by pooling.
 The observed differences in PBMC transcriptomes 
may partially reflect inherited differences in gene regu-
lation between stroke survivors and control subjects. 
Hence, genes from the group of cell–cell signaling genes 
might be promising candidates to search for inherited 
variants associated with stroke risk. In fact, genes coding 
for interleukins and cytokines were considered interest-
ing candidates in several genetic stroke association stud-
ies  [3, 9, 19, 20] .
 However, other factors such as vascular risk factors 
and differences in lifestyle as well as medication might 
have contributed to the observed differences in gene ex-
pression.
 It is a limitation of our study that a second control 
group with vascular risk factors was not investigated. 
This analysis of such a second control group would have 
enabled us to eliminate the potential influence of medica-
tions and vascular risk factors. Further limitations were 
disparities in age and sex between groups and the stimu-
lation of the cells with only a single LPS dose at a single 
time point.
 All survivors were treated with acetylsalicylic acid 
(ASA) or clopidogrel for secondary stroke prevention. 
Moreover, many patients took statins, ACE inhibitors 
and diuretics. Apart from its inhibiting effect on platelet 
aggregation, ASA is an inflammation-modulating drug 
that interferes with cell–cell signaling. High doses of ASA 
inhibited proinflammatory cytokine production in a hu-
man whole blood assay. However, LPS in combination 
with low to moderate doses of ASA modestly enhanced 
the production of proinflammatory cytokines  [21] . Inhi-
bition experiments suggested that the induction of pro-
inflammatory cytokines by ASA was mediated by COX2 
inhibition  [22] . Since COX2 was not downregulated in 
our patients ( fig. 2 ), the increased LPS responsiveness of 
cell–cell signaling genes in the survivors is probably not 
explained by their ASA medication. Clopidogrel treat-
ment is unlikely to explain the increased LPS responsive-
ness of this gene group in our patients, as clopidogrel re-
duces platelet-monocyte aggregation and probably has 
anti-inflammatory effects  [23] .
 Differences in the PBMC transcriptomes from stroke 
survivors and healthy control subjects must not necessar-
ily reflect differential gene activity. Peripheral blood con-
tains a heterogeneous mixture of cells and PBMC isolates 
might differ in their cellular composition. Stroke survi-
vors have increased leukocyte counts  [24] . Flow cytome-
try of whole blood from stroke patients in the convales-
cent phase (3–14 months after acute stroke or transient 
ischemic attack) showed increased platelet activation in 
patients and increased leukocyte-platelet complexes de-
spite antithrombotic therapy  [21] . We characterized each 
PBMC isolate immediately after density gradient centri-
fugation and did not find significant differences. How-
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ever, minor differences between PBMC composition of 
stroke survivors and referents may exist. However, our 
finding that resting cells of survivors and referents have 
similar transcriptomes, but that differences arise upon 
LPS stimulation, is not in favor of differences in PBMC 
composition explaining our findings.
 Stroke is a complex disease. Many studies suggest that 
single genetic variants probably do not confer a large ef-
fect on risk of ischemic stroke [for recent discussion, see 
 25 ]. Since many interacting genetic (and environmental) 
factors seem to modulate the risk of stroke, it is of interest 
to consider functional groups of genes as candidates that 
play a role in the etiology of stroke.
 Most known human genes belong to several gene on-
tology groups. Moreover, the gene ontology groups are 
still under construction and must not be considered as 
complete and definite yet  [26] . The positive result for the 
particular group of cell–cell signaling genes therefore 
suggests, but does not prove, that variation in cell–cell 
signaling plays a role in the pathogenesis of stroke: other 
genetic programs which share many genes with this gene 
ontology group might be involved in this association.
 Two independent statistical evaluations suggested that 
IL18, CXCL11 and G-CSF are among the genes that con-
tribute most strongly to the significant difference in the 
cell–cell signaling gene group. Interleukin-18 (alias IL1  ) 
is a potent proinflammatory cytokine belonging to the 
IL1 family. In diabetic patients elevated plasma IL18 is as-
sociated with carotid intima-media wall thickness, an 
early marker of atherosclerosis  [27] . IL18 was found to be 
highly expressed in human atherosclerotic plaques. Sig-
nificantly higher levels of IL18 mRNA were found in 
symptomatic (unstable) plaques than asymptomatic (sta-
ble) plaques in a real-time PCR study  [28] . Studies in mice 
have shown that exogenously administered IL18 acceler-
ates the rate of atherosclerotic lesion development and 
increases plaque size and inflammatory cell content. 
Conversely, the IL18-binding protein (IL18BP), a natural 
antagonist of IL18, decreases inflammatory cell infiltrate  
 and generates a stable plaque phenotype  [29] . Therefore, 
the elevated LPS-responsiveness of the IL18-gene in cir-
culating cells of our patients with atherothrombotic 
stroke may have contributed to atherogenesis but beyond 
that IL18 may also play a role in brain injury. Elevated 
levels of IL18 were detected in the brains of mice 7 days 
after (traumatic) injury and in human CSF up to 10 days 
after brain trauma. Mice that were treated with IL18BP, a 
specific inhibitor of IL18, 1 h after trauma, showed a sig-
nificantly improved neurological recovery  [30] .
 The chemokine CXCL11 (alias interferon-inducible T-
cell-  chemoattractant) is one of the most potent che-
moattractants of CD4(+) and CD8 T(+) cell transendo-
thelial migration  [31] . The increased LPS responsiveness 
of this gene in stroke patients might suggest that stroke 
survivors display stronger lymphocyte migration upon 
infection or other insults. Moreover, I-TAC/CXCL11 as 
well as MIG/CXCL9 and IP-10/CXCL10 are small pep-
tides with direct antimicrobial activity, similar to human 
defensins  [32] .The cytokine CSF3 (G-CSF) was initially 
described as a hematopoietic growth factor. It is current-
ly studied as a promising candidate for the treatment of 
neurodegenerative conditions because of its anti-inflam-
matory and neurotrophic effects  [33, 34] . It might be 
speculated that the elevated LPS responsiveness of this 
gene in stroke survivors represents a long-term response 
to brain injury. This would imply that the differential ex-
pression of G-CSF might be a late consequence of the 
ischemic stroke event, rather than a preexistent condi-
tion. Indeed only a prospective study could unequivo-
cally identify a gene expression profile associated with an 
increased stroke risk. In such an observational study 
whole genome gene expression profiles must be analyzed 
in a cohort of healthy individuals and associated with fu-
ture ischemic stroke events. The current pilot study was 
merely designed to get a first insight into gene expression 
differences in the peripheral circulation related to stroke 
risk.
 This gene expression analysis of circulating mono-
nuclear leukocytes suggests that the transcriptomes of 
stroke survivors and healthy control subjects are very 
similar under non-stimulated conditions. Whereas rest-
ing PBMCs do not show a pattern of increased expression 
of proinflammatory genes, LPS treatment uncovers dif-
ferent induction of some cell-signaling proteins. G-CSF, 
IL18 and CXCL11 genes mainly contributed to these dif-
ferences in the group of cell–cell signaling genes and 
functional SNPs in these genes may be interesting can-
didates for genetic association studies with stroke pa-
tients.
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